Sirt2的结构功能及其在心血管疾病中的作用机制

摘要/Abstract

摘要： Sirtuin家族是人体中重要的功能蛋白质,其中Sirt2蛋白的作用还不是十分明了,但近些年来,已有许多研究分析了Sirt2蛋白的结构及功能,已基本阐明其在细胞层面和机体代谢水平的重要作用机制。如果Sirt2蛋白不能正常表达,会诱发或加重心血管疾病。该篇综述重点分析了Sirt2蛋白的作用机制及病理情况,综合整理了现今的最新研究成果,便于之后的临床应用,为相关心血管病的诊断和治疗提供新思路。

关键词: Sirt2蛋白, 乙酰化, 心血管疾病

Abstract: The Sirtuin family is a group of important functional proteins in the human body, and the role of Sirt2 protein remains unclear; however, in recent years, studies have been conducted to investigate the structure and function of Sirt2 protein and have basically clarified its important mechanism of action at the cellular level and the metabolic level. The abnormal expression of Sirt2 may induce or aggravate cardiovascular diseases. This article analyzes the mechanism of action of Sirt2 and its role in pathology and summarizes the latest research advances for further clinical application, so as to provide new ideas for the diagnosis and treatment of related cardiovascular diseases.

Key words: Sirt2 protein, Acetylation, Cardiovascular diseases

杨致远, 刘兴琳, 阮佳程, 赵一霖, 文今福, 张凤. Sirt2的结构功能及其在心血管疾病中的作用机制[J]. 心血管病防治知识, 2023, 13(28): 93-96.

YANG Zhi-yuan, LIU Xing-lin, RUAN Jia-cheng, ZHAO Yi-lin, WEN Jin-fu, ZHANG Feng. The structure and function of Sirt2 and its mechanism of action in cardiovascular diseases[J]. Prevention and Treatment of Cardiovascular Disease, 2023, 13(28): 93-96.

参考文献

[1] Schiedel M, Robaa D, Rumpf T, et al.The Current State of NAD(+)-Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets[J]. Medicinal research reviews, 2018, 38(1): 147-200.
[2] 韩可琪,阮昕,贺明.SIRT2在肝癌发生发展中的作用[J]. 上海交通大学学报(医学版)[J]. 2018, 38(10): 1247-1251.
[3] Liu G, Park S H, Imbesi M, et al.Loss of NAD-Dependent Protein Deacetylase Sirtuin-2 Alters Mitochondrial Protein Acetylation and Dysregulates Mitophagy[J]. Antioxidants & redox signaling, 2017, 26(15): 849-863.
[4] Lin S, Xing H, Zang T, et al.Sirtuins in mitochondrial stress: Indispensable helpers behind the scenes[J]. Ageing research reviews, 2018, 44: 22-32.
[5] Yang Y, Liu Y, Wang Y, et al.Regulation of SIRT1 and Its Roles in Inflammation[J]. Frontiers in immunology, 2022, 13: 831168.
[6] Wang S, Zhang J, Deng X, et al.Advances in characterization of SIRT3 deacetylation targets in mitochondrial function[J]. Biochimie, 2020, 179: 1-13.
[7] Hu S, Wang S.The Role of SIRT3 in the Osteoporosis[J]. Frontiers in endocrinology, 2022, 13: 893678.
[8] Min Z, Gao J, Yu Y.The Roles of Mitochondrial SIRT4 in Cellular Metabolism[J]. Frontiers in endocrinology, 2018, 9: 783.
[9] Polletta L, Vernucci E, Carnevale I, et al.SIRT5 regulation of ammonia-induced autophagy and mitophagy[J]. Autophagy, 2015, 11(2): 253-270.
[10] Li W, Feng W, Su X, et al.SIRT6 protects vascular smooth muscle cells from osteogenic transdifferentiation via Runx2 in chronic kidney disease[J]. The Journal of clinical investigation, 2022, 132(1).
[11] Lagunas-Rangel F A. SIRT7 in the aging process[J]. Cellular and molecular life sciences: CMLS, 2022, 79(6): 297.
[12] Zhang H, Head P E, Yu D S.SIRT2 orchestrates the DNA damage response[J]. Cell cycle (Georgetown, Tex), 2016, 15(16): 2089-2090.
[13] North B J, Verdin E.Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis[J]. PloS one, 2007, 2(8): e784.
[14] Inoue T, Hiratsuka M, Osaki M, et al.SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress[J]. Oncogene, 2007, 26(7): 945-957.
[15] Zhang X, Brachner A, Kukolj E, et al.SIRT2 deacetylates GRASP55 to facilitate post-mitotic Golgi assembly[J]. Journal of cell science, 2019, 132(21).
[16] Muth V, Nadaud S, Grummt I, et al.Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription[J]. The EMBO Journal, 2001, 20(6): 1353-1362.
[17] Ishfaq M, Maeta K, Maeda S, et al.The role of acetylation in the subcellular localization of an oncogenic isoform of translation factor eIF5A[J]. Bioscience, biotechnology, and biochemistry, 2012, 76(11): 2165-2167.
[18] Zhou F, Zhang L, Zhu K, et al.SIRT2 ablation inhibits glucose-stimulated insulin secretion through decreasing glycolytic flux[J]. Theranostics, 2021, 11(10): 4825-4838.
[19] Watanabe H, Inaba Y, Kimura K, et al.Sirt2 facilitates hepatic glucose uptake by deacetylating glucokinase regulatory protein[J]. Nature communications, 2018, 9(1): 30.
[20] Tang X, Chen X F, Wang N Y, et al.SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy[J]. Circulation, 2017, 136(21): 2051-2067.
[21] Ren Y R, Ye Y L, Feng Y, et al.SL010110, a lead compound, inhibits gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and improves glucose homeostasis in diabetic mice[J]. Acta pharmacologica Sinica, 2021, 42(11): 1834-1846.
[22] Yang X, Park S H, Chang H C, et al.Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor NRF2[J]. The Journal of clinical investigation, 2017, 127(4): 1505-1516.
[23] Braunwald E.Cardiomyopathies: An Overview[J]. Circulation research, 2017, 121(7): 711-721.
[24] Marian A J, Braunwald E.Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy[J]. Circulation research, 2017, 121(7): 749-770.
[25] Greco C M, Condorelli G.Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure[J]. Nature reviews Cardiology, 2015, 12(8): 488-497.
[26] Zaha V G, Young L H.AMP-activated protein kinase regulation and biological actions in the heart[J]. Circulation research, 2012, 111(6): 800-814.
[27] Chen C, Kassan A, Castaneda D, et al.Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway[J]. Hypertension research: official journal of the Japanese Society of Hypertension, 2019, 42(7): 960-969.
[28] Fassett J T, Hu X, Xu X, et al.AMPK attenuates microtubule proliferation in cardiac hypertrophy[J]. American journal of physiology Heart and circulatory physiology,2013, 304(5): H749-758.
[29] Zeng C, Duan F, Hu J, et al.NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy[J]. Redox biology, 2020, 34: 101523.
[30] He M, Chiang H H, Luo H, et al. An Acetylation Switch of the NLRP3 Inflammasome Regulates Aging-Associated Chronic Inflammation and Insulin Resistance[J]. Cell metabolism, 2020, 31(3): 580-591.e585.
[31] Sun X, Duan J, Gong C, et al.Colchicine Ameliorates Dilated Cardiomyopathy Via SIRT2-Mediated Suppression of NLRP3 Inflammasome Activation[J]. Journal of the American Heart Association, 2022, 11(13): e025266.
[32] Zheng M, Du X, Zhao L, et al.Elevated plasma Sirtuin2 level predicts heart failure after acute myocardial infarction[J]. Journal of thoracic disease, 2021, 13(1): 50-59.
[33] Sarikhani M, Maity S, Mishra S, et al.SIRT2 deacetylase represses NFAT transcription factor to maintain cardiac homeostasis[J]. The Journal of biological chemistry, 2018, 293(14): 5281-5294.
[34] Braunwald E.Heart failure[J]. JACC Heart failure, 2013, 1(1): 1-20.
[35] North B J, Rosenberg M A, Jeganathan K B, et al.SIRT2 induces the checkpoint kinase BubR1 to increase lifespan[J]. The EMBO journal, 2014, 33(13): 1438-1453.
[36] Yang W, Gao F, Zhang P, et al.Functional genetic variants within the SIRT2 gene promoter in acute myocardial infarction[J]. PloS one, 2017, 12(4): e0176245.
[37] Katare P B, Nizami H L, Paramesha B, et al.Activation of toll like receptor 4 (TLR4) promotes cardiomyocyte apoptosis through SIRT2 dependent p53 deacetylation[J]. Scientific reports, 2020, 10(1): 19232.
[38] Mason F E, Pronto J R D, Alhussini K, et al. Cellular and mitochondrial mechanisms of atrial fibrillation[J]. Basic research in cardiology, 2020, 115(6): 72.
[39] Li Y, Liang P, Jiang B, et al.CARD9 promotes autophagy in cardiomyocytes in myocardial ischemia/reperfusion injury via interacting with Rubicon directly[J]. Basic research in cardiology, 2020, 115(3): 29.
[40] Xu S, Ilyas I, Little P J, et al.Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies[J]. Pharmacological reviews, 2021, 73(3): 924-967.
[41] Sabbatinelli J, Prattichizzo F, Olivieri F, et al.Where Metabolism Meets Senescence: Focus on Endothelial Cells[J]. Frontiers in physiology, 2019, 10: 1523.
[42] Münzel T, Camici G G, Maack C, et al.Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series[J]. Journal of the American College of Cardiology, 2017, 70(2): 212-229.
[43] Jagtap P, Szabó C.Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors[J]. Nature reviews Drug discovery, 2005, 4(5): 421-440.
[44] Henning R J, Bourgeois M, Harbison R D.Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders[J]. Cardiovascular toxicology, 2018, 18(6): 493-506.
[45] Hans C P, Zerfaoui M, Naura A S, et al.Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability[J]. Cardiovascular research, 2008, 78(3): 429-439.
[46] Zhang N, Zhang Y, Miao W, et al.An unexpected role for BAG3 in regulating PARP1 ubiquitination in oxidative stress-related endothelial damage[J]. Redox biology, 2022, 50: 102238.
[47] Zhang W, Liu D, Ren J, et al.Overexpression of Sirtuin2 prevents high glucose-induced vascular endothelial cell injury by regulating the p53 and NF-κB signaling pathways[J]. Biotechnology letters, 2018, 40(2): 271-278.
[48] Falk E.Pathogenesis of atherosclerosis[J]. Journal of the American College of Cardiology, 2006, 47(8 Suppl): C7-12.
[49] Dzau V J.Pathobiology of atherosclerosis and plaque complications[J]. American heart journal, 1994, 128(6 Pt 2): 1300-1304.
[50] Macparland S A, Tsoi K M, Ouyang B, et al.Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood[J]. ACS nano, 2017, 11(3): 2428-2443.
[51] Fang S, Xu Y, Zhang Y, et al.Irgm1 promotes M1 but not M2 macrophage polarization in atherosclerosis pathogenesis and development[J]. Atherosclerosis, 2016, 251: 282-290.
[52] Zhang B, Ma Y, Xiang C.SIRT2 decreases atherosclerotic plaque formation in low-density lipoprotein receptor-deficient mice by modulating-macrophage polarization[J]. Biomed Pharmacother, 2018, 97: 1238-1242.